- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT01308489
Minimally Invasive Surgery in Treating Patients With Spinal Tumors
Comparison of Minimally Invasive Approaches of Spine Tumor Surgery
Studie Overzicht
Toestand
Conditie
Gedetailleerde beschrijving
PRIMARY OBJECTIVES:
I. Length of operation (operating room [OR] time). II. Estimated blood loss (EBL). III. Complication rate. IV. Neurological preservation.
SECONDARY OBJECTIVES:
I. Motor strength and sensory level (neurological outcome). II. Bladder and bowel function. III. Post-operative pain. IV. Hospital length of stay (recovery time). V. Arthrodesis.
OUTLINE: Patients are randomized to 1 of 2 treatment arms.
ARM I: Patients undergo posterior spinal tumor resection on day 0.
ARM II: Patients undergo anterior and posterior spinal tumor resection on day 0.
After completion of study treatment, patients are followed up for 6 months.
Studietype
Inschrijving (Werkelijk)
Fase
- Niet toepasbaar
Contacten en locaties
Studie Locaties
-
-
California
-
Duarte, California, Verenigde Staten, 91010
- City of Hope Medical Center
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Patients must have a diagnosis of primary, secondary or metastatic spine tumor and be undergoing any posterior spinal fusion with or without anterior fusion anywhere from occiput to sacrum
- Greater than 3 month life expectancy
- Women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for six months following duration of study participation; should a woman become pregnant or suspect that she is pregnant while participating on the trial, she should inform her treating physician immediately
- All subjects must have the ability to understand and the willingness to sign a written informed consent
Exclusion Criteria:
- Patients who are not surgical candidates for spine tumor removal, determined by the surgical team
- Patients who have undergone previous spine surgery for tumor removal will be excluded
- Patients with renal cell carcinoma
- As there is an emphasis on blood loss and length of surgery, the critical variable for homogeneity is the vascularity of the tumor; hypervascular spine tumors are regarded by surgeons as amongst the most challenging of cases; by far the three most common hypervascular metastatic tumors are those arising from renal cell carcinoma, thyroid carcinoma and melanoma; these pathologies are usually regarded as a distinct subset for this reason in the majority of studies; because we rarely encounter the later two pathologies in our practice, we chose to include only the former; however, to further homogenize our study population we will exclude all three of the known hypervascular metastatic spine tumors
- Subjects, who in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Arm I (posterior spinal tumor resection)
Patients undergo posterior spinal tumor resection on day 0.
|
Nevenstudies
Andere namen:
Undergo posterior spinal tumor resection
Undergo anterior and posterior spinal tumor resection
|
|
Experimenteel: Arm II (anterior and posterior spinal tumor resection)
Patients undergo anterior and posterior tumor resection on day 0.
|
Nevenstudies
Andere namen:
Undergo posterior spinal tumor resection
Undergo anterior and posterior spinal tumor resection
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Estimated blood loss (EBL); in milliliters (ml)
Tijdsspanne: Day 0
|
Will be comparing means with the Wilcoxon test.
|
Day 0
|
|
Length of operation (OR time)
Tijdsspanne: Day 0
|
Will be comparing means with the Wilcoxon test.
|
Day 0
|
|
Complication rate
Tijdsspanne: Day 0
|
Day 0
|
|
|
Neurological preservation
Tijdsspanne: Post operation day 90
|
Post operation day 90
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Length of stay
Tijdsspanne: Less than 7 days
|
Less than 7 days
|
|
|
Pain symptoms
Tijdsspanne: Pre-operation, post-op day 3, discharge, post-op days 7, 28, 60, and 90
|
Pre-operation, post-op day 3, discharge, post-op days 7, 28, 60, and 90
|
|
|
Assessment of neurologic function using the ASIA (American Spinal Injury Association) Impairment Scale
Tijdsspanne: Pre-operation, post-op day 3, discharge, post-op days 7, 28, 60, and 90
|
This is an assessment of sensory and motor functions based upon the ASIA Impairment Scale
|
Pre-operation, post-op day 3, discharge, post-op days 7, 28, 60, and 90
|
|
Evaluation of arthrodesis
Tijdsspanne: Post-op day 1, 28, and 90
|
Plain x-ray films and CT scans are used to determine the success of arthrodesis (spinal fusion in this case) which is the artificial induction of joint ossification between two bones via surgery.
This is done to relieve intractable pain in a joint which cannot be managed by pain medication.
|
Post-op day 1, 28, and 90
|
Medewerkers en onderzoekers
Sponsor
Medewerkers
Onderzoekers
- Hoofdonderzoeker: Rahul Jandial, MD, City of Hope Medical Center
Studie record data
Bestudeer belangrijke data
Studie start
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Schatting)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Pathologische processen
- Ziekten van het centrale zenuwstelsel
- Ziekten van het zenuwstelsel
- Neoplasmata per site
- Neoplastische processen
- Ziekten van het ruggenmerg
- Neoplasmata van het centrale zenuwstelsel
- Neoplasmata van het zenuwstelsel
- Neoplasmata
- Neoplasma metastase
- Neoplasmata van het ruggenmerg
Andere studie-ID-nummers
- 10115 (DAIDS-ES)
- NCI-2011-00231 (Register-ID: CTRP (Clinical Trial Reporting Program))
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .